Conjugate Vaccines
AssigneeGlaxosmithkline Biologicals SA
InventorJan Poolman
Life of this patent
Estimating the term…
Abstract
The invention provides vaccines against Neisseria meningitidis, pneumococcus and DTPa/w. In particular, it provides vaccines based on conjugated capsular saccharides from multiple meningococcal and/or pneumococcal serogroups. It further provides vaccine administration schemes for the immunisation of human patients with two or more of these vaccines.
Claims67
A method for immunizing a human patient against a disease caused by Neisseria meningitidis, comprising the step of administering to the human patient a composition that comprises at least two of:
- (a) a conjugate of (i) the capsular saccharide of serogroup A N.meningitidis and (ii) a tetanus toxoid or derivative thereof;
- (b) a conjugate of (i) the capsular saccharide of serogroup C N.meningitidis and (ii) a tetanus toxoid or derivative thereof;
- (c) a conjugate of (i) the capsular saccharide of serogroup W135 N.meningitidis and (ii) a tetanus toxoid or derivative thereof;
- and (d) a conjugate of (i) the capsular saccharide of serogroup Y N.meningitidis and (ii) a tetanus toxoid or derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than N.meningitidis and (ii) a tetanus toxoid or derivative thereof.
A method for immunizing a human patient against a disease caused by Neisseria meningitidis, comprising the step of administering to the human patient a composition that comprises at least two of:
- (a) a conjugate of (i) the capsular saccharide of serogroup A N.meningitidis and (ii) a tetanus toxoid;
- (b) a conjugate of (i) the capsular saccharide of serogroup C N.meningitidis and (ii) a tetanus toxoid;
- (c) a conjugate of (i) the capsular saccharide of serogroup W135 N.meningitidis and (ii) a tetanus toxoid;
- and (d) a conjugate of (i) the capsular saccharide of serogroup Y N.meningitidis and (ii) a tetanus toxoid, wherein the patient has been pre-immunised with (a) a tetanus toxoid and/or (b) a conjugate of (i) a capsular saccharide of an organism other than N. meningitidis and (ii) a tetanus toxoid.
3-4. (canceled)
(canceled)
A method for immunizing a human patient against a disease caused by Streptococcus pneumoniae, comprising the step of administering to the human patient a composition that comprises at least seven conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which is conjugated to a diphtheria toxoid or CRM197 or a derivative thereof, wherein the patient has been pre-immunised with (a) a diphtheria toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.
A method for immunizing a human patient against a disease caused by Streptococcus pneumoniae, comprising the step of administering to the human patient a composition that comprises at least seven conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which is conjugated to tetanus toxoid or a derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof.
A method for immunizing a human patient against a disease caused by Streptococcus pneumoniae, comprising the step of administering to the human patient a composition that comprises at least seven conjugates of different capsular saccharide serotypes of pneumococcus, at least one of which is conjugated to tetanus toxoid or a derivative thereof and at least one of which is conjugated to diphtheria toxoid or CRM197 or a derivative thereof, wherein the patient has been pre-immunised with (a) a tetanus toxoid or derivative thereof and/or (b) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a tetanus toxoid or derivative thereof and (c) a diphtheria toxoid or derivative thereof and/or (d) a conjugate of (i) a capsular saccharide of an organism other than pneumococcus and (ii) a diphtheria toxoid or CRM197 or derivative thereof.
25-27. (canceled)
A method for immunizing a human patient against a disease caused by Neisseria meningitidis, Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae and Streptococcus pneumoniae comprising the step of administering to the human patient the following vaccines with the following administration scheme:
- Visit 1
- Visit 2
- Visit 3
- Visit 4
- DTP
- X
- X
- Strep
- X
- X
- MenC
- X
- X
- wherein the visit to the medical practitioner all occur in the first 8 months of life,
- wherein there is at least 2 weeks between each consecutive visit,
- wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
- wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
- wherein MenC comprises a conjugated N. meningitidis serogroup C capsular saccharide,
- wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.
A method for immunizing a human patient against a disease caused by Neisseria meningitidis, Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae and Streptococcus pneumoniae comprising the step of administering to the human patient the following vaccines with the following administration scheme:
- Visit 1
- Visit 2
- Visit 3
- Visit 4
- DTP
- X
- X
- X
- Strep
- X
- X
- MenC
- X
- Optionally X
- wherein the visit to the medical practitioner all occur in the first 8 months of life,
- wherein there is at least 2 weeks between each consecutive visit,
- wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
- wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
- wherein MenC comprises a conjugated N. meningitidis serogroup C capsular saccharide,
- wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.
A method for immunizing a human patient against a disease caused by Neisseria meningitidis, Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae and Streptococcus pneumoniae comprising the step of administering to the human patient the following vaccines with the following administration scheme:
- Visit 1
- Visit 2
- Visit 3
- DTP
- X
- X
- X
- Strep
- X
- X
- MenC
- X
- X
- wherein the visit to the medical practitioner all occur in the first 8 months of life,
- wherein there is at least 2 weeks between each consecutive visit,
- wherein DTP comprises DT, TT, and either whole cell (Pw) or acellular (Pa) pertussis antigens,
- wherein Strep is a multivalent pneumococcal capsular saccharide conjugate vaccine comprising at least 7, 10, 11, 13 or 14 conjugated serotypes,
- wherein MenC comprises a conjugated N. meningitidis serogroup C capsular saccharide,
- wherein at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to DT or CRM197, or at least one conjugated saccharide in each of the Strep and MenC vaccines is conjugated to TT.
(canceled)
Dependencies are inferred from the claim text.